SPONSOR
French Innovative Leukemia Organisation
Total Trials
3
Recruiting
3
Phases
Phase 2
Conditions studied: AML, AdultRefractory AMLRelapsed Adult AMLFLT3-TKD MutationFLT3-ITDBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
French Innovative Leukemia Organisation is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — French Innovative Leukemia Organisation
How many clinical trials has French Innovative Leukemia Organisation sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by French Innovative Leukemia Organisation, of which 3 are actively recruiting participants. These trials cover conditions including AML, Adult, Refractory AML, Relapsed Adult AML. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does French Innovative Leukemia Organisation research focus on?
French Innovative Leukemia Organisation clinical trials span AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a French Innovative Leukemia Organisation clinical trial?
To participate in a French Innovative Leukemia Organisation trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all French Innovative Leukemia Organisation trials with current recruitment status updated daily.
Clinical Trials by French Innovative Leukemia Organisation
NCT06022003 Phase 2
Recruiting
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
AML, Adult
NCT06377579
Recruiting
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
AML, Adult
NCT07007052 Phase 2
Recruiting
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology